title: Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression.
abstract: BACKGROUND
  Reduced dopaminergic transmission has been implicated in the pathophysiology of major depression. The aim of the present study was to measure striatal D(2) receptor availability and amphetamine-induced dopamine release in nonpsychotic, unmedicated, unipolar patients during an episode of major depression.
  
  
  METHODS
  The striatal equilibrium specific to nonspecific partition coefficient (V(3)") of the D(2) receptor antagonist [(123)I]IBZM was measured with single photon emission computerized tomography before and after amphetamine administration in 9 depressed subjects and 10 matched healthy control subjects.
  
  
  RESULTS
  No significant differences were observed in preamphetamine D(2) receptor availability between depressed patients (0.73 +/- 0.08) and control subjects (0.78 +/- 0.10, p =.23). Amphetamine-induced reduction in [(123)I]IBZM V(3)" (DeltaV(3)") was similar in depressed patients (-9.8 +/- 5.5%) and control subjects (-7.8 +/- 2.5%, p =.32). Amphetamine induced a transient improvement in symptomatology in depressed patients, but this improvement did not correlate with [(123)I]IBZM DeltaV(3)".
  
  
  CONCLUSIONS
  This study did not replicate previously reported alterations in striatal D(2) receptor density in depressed patients and suggests that stimulant-induced dopamine release is not altered in major depression.
authors.affiliation: Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: R V
authors.initials: RV
authors.lastname: Parsey
authors.forename: M A
authors.initials: MA
authors.lastname: Oquendo
authors.forename: Y
authors.initials: Y
authors.lastname: Zea-Ponce
authors.forename: J
authors.initials: J
authors.lastname: Rodenhiser
authors.forename: L S
authors.initials: LS
authors.lastname: Kegeles
authors.forename: M
authors.initials: M
authors.lastname: Pratap
authors.forename: T B
authors.initials: TB
authors.lastname: Cooper
authors.forename: R
authors.initials: R
authors.lastname: Van Heertum
authors.forename: J J
authors.initials: JJ
authors.lastname: Mann
authors.forename: M
authors.initials: M
authors.lastname: Laruelle
mesh_terms: D000293:Adolescent; D000328:Adult; D000661:Amphetamine / Q000493:pharmacokinetics / Q000494:pharmacology*; D001549:Benzamides; D003342:Corpus Striatum / Q000000981:diagnostic imaging / Q000503:physiopathology*; D003865:Major Depressive Disorder / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000523:psychology; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001549:Benzamides; D007457:Iodine Radioisotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D000661:Amphetamine; D004298:Dopamine